Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00221312 · ClinicalTrials.gov registry record
Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 48
- Enrollment target
NCT00221312 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 48 participants.
The verdict
NCT00221312 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years preceding the menopause (perimenopausal transition). During the three to five years prior to the menopause, the rate of bone loss increases. One way that physicians treat this is with oral contraceptive medication. However, the incidence of complications from oral contraceptives after the age of 40 increases. Therefore, a non-hormonal means of preventing bone loss should be useful. Fosamax (alendronate) is in a class of compounds called bisphosphonates. This study is being done to determine whether Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition.
Interventions
- DRUG Fosamax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2002-05 |
| Est. Completion | 2007-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00221312
The ClinicalTrials.gov registry entry for NCT00221312 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fosamax is the first listed.
NCT00221312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00221312 about?
NCT00221312 is a clinical study titled "Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss". This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years ...
What is the current status of trial NCT00221312?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2002-05. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00221312?
The interventions under investigation include: Fosamax (DRUG).
Who is sponsoring clinical trial NCT00221312?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.